Advanced search
Publication Cover
Autoimmunity Volume 57, 2024 - Issue 1
Submit an article Journal homepage
1,667
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Interplay between COVID-19 and Secukinumab treatment in Spondylarthritis patients during the omicron surge: a retrospective cohort study

Tong Wua Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China;b Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;c Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, ChinaView further author information
,
Yanhong Lia Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China;b Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;c Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, ChinaView further author information
,
Deying Huanga Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China;b Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;c Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, ChinaView further author information
,
Yinlan Wua Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China;b Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;c Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, ChinaView further author information
,
Xiuping Lianga Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China;b Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;c Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, ChinaView further author information
,
Lu Chenga Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China;b Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;c Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, ChinaView further author information
,
Zehui Liaod Meishan People’s Hospital, Meishan, ChinaView further author information
,
Fang Xud Meishan People’s Hospital, Meishan, ChinaView further author information
,
Ye Chena Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China;b Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;c Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, ChinaView further author information
,
Jing Zhaoa Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China;b Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;c Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, ChinaView further author information
,
Zijing Xiaa Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China;b Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;c Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, ChinaView further author information
,
Chunyu Tana Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China;b Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;c Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, ChinaCorrespondence[email protected]
View further author information
,
Yi Liua Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China;b Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;c Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, ChinaCorrespondence[email protected]
View further author information
&
Martin Herrmanne Department of Medicine 3, Universitäts-klinikum Erlangen, Erlangen, Germany;f Deutsches Zentrum Immuntherapie DZI, Universitätsklinikum Erlangen, Erlangen, GermanyView further author information
 show all
Article: 2281242 | Received 07 Jul 2023, Accepted 05 Nov 2023, Published online: 13 Dec 2023

Figures & data

Figure 1. Flowchart for patient selection.

Figure 1. Flowchart for patient selection.

Table 1. Comparison of baseline characteristics, medication use, and disease course in as and PsA patients.

Table 2. Comparison of SARS-CoV-2 infection rate and COVID-19 outcomes in Secukinumab and cohabitants control group.

Table 3. Comparison of characteristics, medication use, disease course and COVID-19 outcomes in exacerbation group and stable group.

Supplemental material

Supplemental Material

Download Zip (28 KB)

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.